SOX2 and breast cancer: In a previous study, researchers engineered three ATFs that bind to the proximal SOX2 promoter and one ATF that targets SOX2 regulatory region I (SRR1), one of which inhibits the expression of SOX2 in breast cancer cells by as much as 94% [173].